Thu. Mar 23rd, 2023

Vaxart, Inc.

Firm to present a detailed overview of its norovirus clinical plan

Webcast to be held on March 28, 2023 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) now announced it will host a important opinion leader video webcast on the overall health and financial effect and illness burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

The webcast will function presentations by prominent norovirus illness specialists Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Centers for Illness Manage &amp Prevention, and Sarah Bartsch, Project Director, Public Overall health Informatics, Computational, and Operations Study, Study Foundation of the City University of New York.

In addition, Vaxart management will present a detailed overview of the Company’s investigational norovirus oral pill vaccine plan, which includes its two existing Phase two clinical trials:

  • An ongoing Phase two GI.1 norovirus challenge study measuring the efficacy and security of our norovirus vaccine candidate. The study is also made to determine a correlate of protection amongst immune responses to the vaccine and a reduction in threat of norovirus infection and / or serious gastroenteritis. The Firm expects to report topline information from this study in Q3 2023.

  • A Phase two dose-ranging study of Vaxart’s bivalent norovirus oral vaccine candidate is made to determine a vaccine dose for a prospective Phase three clinical trial. The Firm expects to report topline information from this study in mid-2023.

To register for the webcast, please click right here. A replay of the webcast will be accessible on the Company’s web site at following the conclusion of the occasion.

About the KOLs

Jan Vinjé, Ph.D.
Dr. Vinjé is head of the National Calicivirus Laboratory and Director of CaliciNet at the Centers for Illness Manage and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. degree at the University of Utrecht, the Netherlands, in 1999. Right after getting a postdoctoral fellowship and an appointment as analysis assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. More than the previous ten years, he has served on many plan advisory committees from many European analysis projects (FP6, FP7). He is serving as technical specialist on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is a member of the International Committee on Taxonomy of Viruses study groups on Caliciviridae (chair as of 2014) and Astroviridae. He is presently a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Meals and Environmental Virology, and he serves as an ad hoc reviewer for numerous higher-effect journals. Dr. Vinjé has published more than one hundred peer-reviewed publications and many book chapters. His analysis interests involve all elements of viral gastrointestinal illness, which includes detection, characterization, and prevention and manage of norovirus infections.

Story continues

Sarah M. Bartsch, MPH
Ms. Bartsch is a Project Director and Senior Analyst with Public Overall health Informatics, Computational, and Operations Study (PHICOR), the Artificial Intelligence, Modeling, and Informatics for Nutrition Guidance and Systems (AIMINGS) Center, and the Center for Sophisticated Technologies and Communication in Overall health (CATCH), headquartered at the City University of New York (CUNY) Graduate College of Public Overall health and Overall health Policy. She has been a aspect of the group considering that August of 2009 and has more than a decade of encounter employing systems approaches and building mathematical and computational models to help a wide variety of selection makers in public overall health. Bartsch has authored more than 95 scientific publications, which includes much more than 30 as very first author.

About Vaxart 
Vaxart is a clinical-stage biotechnology organization building a variety of oral recombinant vaccines primarily based on its proprietary delivery platform. Vaxart vaccines are made to be administered employing tablets that can be stored and shipped without the need of refrigeration and remove the threat of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is appropriate to provide recombinant vaccines, positioning the organization to create oral versions of presently marketed vaccines and to design and style recombinant vaccines for new indications. Vaxart’s improvement applications presently involve pill vaccines made to defend against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as effectively as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s very first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technologies and creations for oral vaccination employing adenovirus and TLR3 agonists.

Note Relating to Forward-Searching Statements
This press release includes forward-seeking statements that involve substantial dangers and uncertainties. All statements, other than statements of historical information, incorporated in this press release relating to Vaxart’s approach, prospects, plans and objectives, benefits from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-seeking statements. These forward-seeking statements may perhaps be accompanied by such words as “ought to,” “think,” “could,” “prospective,” “will,” “anticipated,” “anticipate,” “strategy,” and other words and terms of comparable which means. Examples of such statements involve, but are not restricted to, statements relating to Vaxart’s potential to create and commercialize its item candidates, which includes its vaccine booster items Vaxart’s expectations relating to clinical benefits and trial information and Vaxart’s expectations with respect to the effectiveness of its item candidates. Vaxart may perhaps not in fact attain the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-seeking statements, and you ought to not location undue reliance on these forward-seeking statements. Actual benefits or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-seeking statements. Many significant things could bring about actual benefits or events to differ materially from the forward-seeking statements that Vaxart tends to make.

Please also refer to the dangers described in the “Threat Things” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-seeking statements, except as expected by law.


Investor Relations:

Andrew Blazier

FINN Partners

(646) 871-8486

By Editor

One thought on “Vaxart to Host Webcast with Essential Opinion Leaders to Go over the Overall health Effect and Illness Burden for Norovirus”

Leave a Reply